Skip to main content

Advertisement

Table 4 Overall situation of evidence support for the effectiveness of anti-hypertensive medicines in NRDL

From: Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List

  Sound evidence support Subtotal Insufficient evidence support Subtotal
Support from international evidence-based drug list Support from systematic review or meta-analysis Support from RCT Reported by RCT with poor quality No evidence involved No definite conclusion in systematic review or meta-analysis
Calcium antagonist 7 (29.2%) 6 (25.0%) 1 (4.2%) 14 (58.3%) 0 (0.0%) 7 (29.2%) 3(12.5%) 10 (41.7%)
β blockers 6 (42.9%) 3 (21.4%) 1 (7.1%) 10 (71.4%) 1 (7.1%) 2 (14.3%) 1 (7.1%) 4 (28.6%)
Diuretics 4 (36.4%) 0 (0.0%) 2(18.2%) 6 (54.6%) 0 (0.0%) 5 (45.4%) 0 (0.0%) 5 (45.4%)
ACEIs 3 (20.0%) 4 (26.7%) 4(26.7%) 11 (73.3%) 1 (6.7%) 3 (20.0%) 0 (0.0%) 4 (26.7%)
Angiotensin II receptor antagonist 5 (41.7%) 2 (16.6%) 1 (8.3%) 8 (66.7%) 0 (0.0%) 4 (33.3%) 0 (0.0%) 4 (33.3%)
Vasodilators 0 (0.0%) 1 (14.3%) 0 (0.0%) 1 (14.3%) 0 (0.0%) 5 (71.4%) 1 (14.3%) 6 (85.7%)
Others 1 (7.1%) 4 (28.6%) 1 (7.1%) 6 (42.9%) 0 (0.0%) 7 (50.0%) 1 (7.1%) 8 (57.1%)
Class A 13 (50.0%) 4 (15.4%) 1 (3.8%) 18 (69.2%) 1 (3.8%) 6 (23.1%) 1 (3.8%) 8 (30.8%)
Class B 13 (18.3%) 16 (22.6%) 9 (12.7%) 38 (53.5%) 1 (1.4%) 27 (38.1%) 5 (7.0%) 33 (46.5%)
Total 26 (26.8%) 20 (20.6%) 10 (10.3%) 56 (57.7%) 2 (2.1%) 33 (34.0%) 6 (6.2%) 41 (42.3%)